Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
Jimenez-Murcia S, Granero R, Larrea ST, Sauvaget A, Grall-Bronnec M, Alvarez-Moya EM, Aguera Z, Aymami N, Gomez-Pena M, Del Pino-Gutierrez A, Moragas L, Menchon JM, Fagundo AB, Sauchelli S, La Verde M, Aguglia E, Signorelli MS, Formoso JAF, Fernandez-Aranda F. Pathological gambling and substance use disorders: effects of early incidence and personality. Drugs Health Society. 2015 Jan;14(1):78. doi: 10.7202/1035550ar
Hirsch IB, Xu Y, Davis KL, Calingaert B. Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin. Endocr Pract. 2011 Sep 1;17(5):707-16.
Tunceli K, Pladevall-Vila M, Williams LK, Divine GW, Simpkins JC, Nag SS, Sajjan SG, Kamal-Bahl SJ, Alexander CM, Lafata JE. Trends in lipid management among patients with diabetes. Endocr Pract. 2006 Jul;12(4):380-7.